[Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
To determine the level of tumor marker pyruvate kinase dimer (M2-PK) in the feces of patients with colorectal cancer and benign polyps, as well as in individuals with chronic inflammatory bowel diseases. Fecal M2-PK determination could be outlined as a highly reliable non-invasive approach to the diagnosis of colorectal carcinoma. The establishing of elevated values in patients with chronic inflammatory bowel diseases decreases the specificity of M2-PK as a tumor marker. However, this does not compromise its essential clinical significance, because the precise diagnosis in both diseases imposes an obligatory performance of colonoscopy.
Ivanova
A
A
Iarŭmov
N
N
Toshev
S
S
Adzharov
D
D
Krŭstev
Z
Z
Angelov
K
K
Sokolov
M
M
Gribnev
P
P
D003111:Colonic Polyps / Q000175:diagnosis / Q000201:enzymology; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000201:enzymology; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011770:Pyruvate Kinase / Q000032:analysis* / Q000378:metabolism; D012680:Sensitivity and Specificity
D011770:Pyruvate Kinase